Poster Session E - Tuesday Afternoon
Category: IBD
Fabricio Furlan
Hexal AG (a Sandoz company)
Holzkirchen, Bayern, Germany
Primary system organ class Preferred term | GP2017-HCF N=162 n (%) | GP2017 N=168 n (%) |
Number of subjects with at least 1 event | 80 (49.4) | 95 (56.5) |
General disorders and administration site conditions | 55 (34.0) | 69 (41.1) |
Investigations | 16 (9.9) | 24 (14.3) |
Musculoskeletal and connective tissue disorders | 8 (4.9) | 14 (8.3) |
Nervous system disorders | 8 (4.9) | 6 (3.6) |
Skin and subcutaneous tissue disorders | 10 (6.2) | 4 (2.4) |
Gastrointestinal disorders | 8 (4.9) | 3 (1.8) |
Respiratory, thoracic and mediastinal disorders | 2 (1.2) | 6 (3.6) |
Eye disorders | 1 (0.6) | 4 (2.4) |
Injury, poisoning and procedural complications | 4 (2.5) | 1 (0.6) |